Tvardi Therapeutics (NASDAQ:TVRD) Rating Increased to Hold at Wall Street Zen

Tvardi Therapeutics (NASDAQ:TVRD) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Sunday.

Several other brokerages have also recently commented on TVRD. Cantor Fitzgerald cut Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, October 13th. Barclays set a $5.00 price objective on Tvardi Therapeutics and gave the stock an “equal weight” rating in a research note on Monday, October 13th. Raymond James Financial cut shares of Tvardi Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, October 14th. Weiss Ratings restated a “sell (e)” rating on shares of Tvardi Therapeutics in a report on Monday, December 15th. Finally, Piper Sandler lowered shares of Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, October 13th. Three research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $55.50.

Tvardi Therapeutics Trading Up 2.3%

Shares of NASDAQ:TVRD opened at $3.98 on Friday. The firm has a market cap of $37.33 million, a P/E ratio of -0.41 and a beta of 0.11. Tvardi Therapeutics has a twelve month low of $3.74 and a twelve month high of $43.65. The company has a 50 day moving average of $4.56 and a 200-day moving average of $20.36.

Tvardi Therapeutics (NASDAQ:TVRD) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.24. Tvardi Therapeutics had a negative net margin of 585.37% and a negative return on equity of 282.16%.

Hedge Funds Weigh In On Tvardi Therapeutics

Several large investors have recently modified their holdings of TVRD. Geode Capital Management LLC bought a new stake in shares of Tvardi Therapeutics during the 2nd quarter worth about $2,617,000. JPMorgan Chase & Co. acquired a new stake in Tvardi Therapeutics during the second quarter worth approximately $39,000. New York State Common Retirement Fund bought a new stake in shares of Tvardi Therapeutics during the second quarter worth approximately $92,000. Marshall Wace LLP bought a new stake in shares of Tvardi Therapeutics during the second quarter worth approximately $583,000. Finally, Slate Path Capital LP acquired a new position in shares of Tvardi Therapeutics in the second quarter valued at approximately $16,427,000. 44.66% of the stock is owned by institutional investors.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.